Latest Headlines

Latest Headlines

AstraZeneca uses snails and overstuffed luggage to push OIC awareness--and its branded solution

No one wants to talk about constipation. Except AstraZeneca. On national television. To the tune of almost $10 million in media spending since late June, according to real-time TV ad tracker iSpot.tv.

Syndax banks an $80M crossover round for PhIII cancer drug

Two months after signing up AstraZeneca R&D leader Briggs Morrison as its new CEO, Waltham, MA-based Syndax has raised $80 million from a syndicate that includes a group of high-profile crossover investors.

AstraZeneca lures Sean Bohen from Genentech to fill top R&D post

AstraZeneca has filled the vacancy at the head of its R&D organization. Sean Bohen is set to take up the post next month after being persuaded to swap a position at the heart of early-stage R&D at Genentech for a chance to guide AstraZeneca's late-phase hopefuls toward approval.

AstraZeneca continues I-O deal spree with PD-L1 combo trial hookup

AstraZeneca has struck its fourth immuno-oncology deal in as many weeks. The latest deal in the flurry of activity sees AstraZeneca hook up with Peregrine Pharmaceuticals to add another study to the burgeoning list of PD-L1 checkpoint inhibitor combination trials.

India's Lee Pharma turned down on CL challenge to AZ's Onglyza

India's Controller of Patents has turned down a compulsory license application by Lee Pharma to make a version of AstraZeneca's Onglyza, citing competing substitutes already in the market and patent terms, the  Economic Times  reported.

Stalwart brands from AZ, Glaxo and Sanofi top ranks of most-prescribed meds

We've heard pharma's latest numbers on individual product sales. We know how each company's drugs stack up internally. But how are the top-prescribed brands doing in the overall industry horse race?   

AstraZeneca backs Aussie smart inhaler startup Adherium in $26M IPO

Australian smart inhaler player Adherium has raised AU$35 million ($25.8 million) in an IPO that's supported by its big pharma partner AstraZeneca. The biopharma committed to kicking in $3 million of the IPO fundraising, which was reported 2x oversubscribed by investors.

AZ's MedImmune offers up $727M to get its hands on Inovio cancer vaccine

MedImmune on Monday announced a development deal worth up to $727 million--$27 million upfront--to acquire exclusive rights to Inovio Pharmaceuticals' HPV cancer vaccine INO-3112 and to develop additional cancer vaccine candidates.

UPDATED: AstraZeneca offers $727M package to partner with Inovio on immuno-oncology

AstraZeneca's big MedImmune subsidiary has nailed down its third pact in 5 days, inking a collaboration with Inovio Pharmaceuticals on a cancer vaccine designed to generate a tumor-specific T cell response. MedImmune is handing over a $27.5 million upfront and up to $700 million in milestones for the deal while agreeing to also cover the research tab.

AstraZeneca recalls inhalers in Denmark that may contain no drug

For an asthmatic who reaches for their inhaler to discover it contains no drug could be troubling, but that is the chance in Denmark, where AstraZeneca is recalling potentially empty devices.